Synapse - Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy Meeting Abstract

Authors:	Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; Jhaveri, K.; Modi, S.; Troso-Sandoval, T.; Jack, K.; Ulaner, G.; Jochelson, M.; Baselga, J.; Norton, L.; Hudis, C. A.; Dang, C. T.
Abstract Title:	Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
Meeting Title:	42nd ESMO Congress (ESMO 2017)
Journal Title:	Annals of Oncology
Volume:	28
Issue:	Suppl. 5
Meeting Dates:	2017 Sep 8-12
Meeting Location:	Madrid, Spain
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2017-09-01
Start Page:	mdx365.015
Language:	English
ACCESSION:	WOS:000411324000241
PROVIDER:	wos
DOI:	10.1093/annonc/mdx365.015
Notes:	Meeting Abstract: 252P -- Appears on page 81 of the abstract book -- Source: Wos